Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics Inc. (ADMA) is a commercial-stage biopharmaceutical company advancing plasma-derived therapies for immune deficiencies and infectious diseases. This dedicated news hub provides verified updates on corporate developments, regulatory milestones, and clinical progress.
Investors and healthcare professionals will discover timely coverage of earnings announcements, FDA decisions, manufacturing innovations, and strategic partnerships. Our curated selection emphasizes ADMA’s operational achievements in plasma collection, biomanufacturing excellence, and therapeutic pipeline advancements.
Key updates include product authorization progress, financial disclosures, patent developments, and peer-reviewed research findings. All content undergoes rigorous verification to ensure accuracy for investment and industry analysis.
Bookmark this page for direct access to ADMA’s official communications and expertly contextualized news. Maintain awareness of critical developments impacting this innovative biologics manufacturer through Stock Titan’s trusted reporting.
ADMA Biologics reported outstanding third quarter 2024 results with total revenue of $119.8 million, up 78% year-over-year. The company achieved GAAP Net Income of $35.9 million, a 1,300% increase, and Adjusted EBITDA of $45.4 million, up 256%. Gross profits reached $59.7 million with a 50% margin. ADMA increased its guidance for FY 2024, expecting revenue over $415 million and GAAP net income exceeding $120 million. The company's higher-margin product ASCENIV now accounts for over 50% of total revenue. ADMA also joined the S&P SmallCap 600 Index and appointed KPMG LLP as its new independent auditor.
ADMA Biologics (Nasdaq: ADMA) has announced it will report its third quarter 2024 financial results on November 7, 2024, after U.S. market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. Participants can dial (888) 596-4144 with conference ID 2959956 to join the call. A webcast will be available for those not asking questions, and an archived replay will be accessible through the company's investor relations website.
ADMA Biologics (Nasdaq: ADMA), a biopharmaceutical company specializing in specialty biologics, has announced its inclusion in the S&P SmallCap 600 index, effective September 23, 2024. This milestone is expected to increase ADMA's visibility among investors and enhance share liquidity. The S&P SmallCap 600 index, designed to measure the small-cap segment of the U.S. equity market, comprises 600 companies meeting specific criteria for liquidity and financial viability.
Adam Grossman, ADMA's President and CEO, emphasized the significance of this inclusion as the company continues to execute its growth strategy. The move reflects ADMA's progress and potential in the biopharmaceutical sector, particularly in manufacturing, marketing, and developing specialty biologics.
ADMA Biologics, Inc. (Nasdaq: ADMA), a commercial biopharmaceutical company focused on specialty biologics, has announced its participation in the 2024 Cantor Global Healthcare Conference. The event will take place in New York, NY on September 17, 2024.
Key details:
- Adam Grossman, President and CEO, will participate in a fireside chat
- The presentation is scheduled for 3:05 p.m. ET
- A live audio webcast will be available on the company's investor relations website
- An archived version of the webcast will be accessible approximately two hours after the event
This conference provides ADMA Biologics with an opportunity to showcase its progress and strategy to investors and industry professionals in the healthcare sector.
ADMA Biologics has announced a partial paydown of its revolving credit facility, utilizing $30 million of cash on hand to repay Ares Capital. This move reduces ADMA's total debt to $105 million, a 22% reduction from its previous level. The company's debt now consists of a $62.5 million term loan and $42.5 million outstanding under the revolving credit facility. ADMA's President and CEO, Adam Grossman, stated that this decision reflects the company's confidence in sustained earnings growth and anticipated ongoing cash generation. The reduced interest expense is expected to enhance earnings growth potential in the near future. ADMA plans to further optimize its cost of both debt and equity capital moving forward.
ADMA Biologics reported a strong second quarter for 2024, showcasing a 78% increase in revenue year-over-year, reaching $107.2 million. The company achieved a GAAP net income of $32.1 million, signaling a $38.4 million improvement from the prior year. The Adjusted EBITDA grew nearly 600% to $44.5 million. ADMA's innovative biologics manufacturing process has the potential to boost yield by approximately 20%.
For FY 2024 and 2025, ADMA raised its revenue guidance to over $400 million and $445 million, respectively. Net income guidance for FY 2024 and 2025 was also increased to more than $105 million and $155 million, respectively. The company expects Adjusted EBITDA to exceed $150 million in 2024 and $200 million in 2025.
ADMA's higher margin product portfolio now accounts for over 50% of total revenue. The second quarter also saw improvements in ADMA's balance sheet and expansion of their ADMAlytics™ program.
ADMA Biologics (Nasdaq: ADMA) has announced it will report its second quarter 2024 financial results on August 8, 2024, after the U.S. financial markets close. The company's management team will host a live conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the financial results and provide company updates.
Participants can register for the call to receive dial-in numbers and a unique PIN. It's recommended to join about 10 minutes before the event starts. Those not asking questions are encouraged to listen to the live webcast. An archived replay will be available in the investor section of ADMA's website.
ADMA Biologics reported impressive first quarter 2024 financial results, with a total revenue of $81.9 million, a 44% increase year-over-year. The GAAP net income was $17.8 million, a $24.6 million increase year-over-year. Adjusted EBITDA for Q1 2024 was $26.4 million, a 970% increase year-over-year. The company raised its total revenue guidance for FY 2024 to more than $355 million and for FY 2025 to more than $410 million. Net income guidance was also increased for both years, as well as Adjusted EBITDA guidance. ADMA highlighted the success of its ASCENIV™ and BIVIGAM® products in driving commercial growth and reaffirmed its commitment to immune deficient patients. The company is focused on advancing growth initiatives, including biologics production processes and preclinical pipeline programs, to exceed expectations and deliver value to stakeholders.
ADMA Biologics, Inc. (Nasdaq: ADMA) will report its first quarter 2024 financial results on May 9, 2024. The live conference call and audio webcast will be hosted by the management team at 4:30 p.m. ET on the same day to discuss the financial results and Company updates. Participants can register for the call to receive the dial-in numbers and unique PIN. An archived replay will be available on the Company's investor website.
FAQ
What is the current stock price of Adma Biologics (ADMA)?
What is the market cap of Adma Biologics (ADMA)?
